Allopurinol for the treatment of chronic kidney disease: a systematic review

Nigel Fleeman,1* Gerlinde Pilkington,1 Yenal Dundar,1 Kerry Dwan,1 Angela Boland,1 Rumona Dickson,1 Hameed Anijeet,2 Tom Kennedy2 and Jason Pyatt2

1Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
2Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK

*Corresponding author

Declared competing interests of authors: none

Published June 2014
DOI: 10.3310/hta18400

Plain English summary

Allopurinol for the treatment of CKD
Health Technology Assessment 2014; Vol. 18: No. 40
DOI: 10.3310/hta18400

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

Allopurinol is a drug commonly used to treat increased blood uric acid levels in patients with gout. Evidence is emerging that it may also have a role to play in patients with chronic kidney disease, in that it may slow down the progression of the disease and also reduce the risk of heart disease.

We reviewed the available studies to consider whether or not using allopurinol in people with chronic kidney disease may prevent the worsening of their disease. Our review found that there was limited evidence that allopurinol slows down the progression of chronic kidney disease or reduces the occurrence of heart disease. However, this evidence was not convincing as it was derived from studies with small numbers of patients and similar findings were not reported from more than one study. We did identify that there are very few serious side effects from taking the treatment. However, we cannot say whether or not patients with kidney disease taking allopurinol have the same side effects as patients taking the drug for other conditions such as gout. Therefore, we have concluded that additional research is required, ideally including a trial with a larger number of people with chronic kidney disease.
Criteria for inclusion in the \textit{Health Technology Assessment} journal

Reports are published in \textit{Health Technology Assessment} (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in \textit{Health Technology Assessment} are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

\section*{HTA programme}

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: www.hta.ac.uk/

\section*{This report}

The research reported in this issue of the journal was funded by the HTA programme as project number 12/45/01. The contractual start date was in December 2012. The draft report began editorial review in May 2013 and was accepted for publication in January 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2014. This work was produced by Fleeman et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

Professor Jane Norman  Professor of Maternal and Fetal Health, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, University College London, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk